Hey douchbag, who do you work for. Day and night bashing. Fleck in loser
never saw anything so stupid. your right. alibaba scamming numbers and here they have actual inventory and they ship it out themselves.
they turned profitable. should rise when market opens. Alibaba has to many problems its a joke.
MACENTA, Guinea (Thomson Reuters Foundation) - In a land where witchcraft is sought after more than science for curing illness, medicine men in Guinea say the Ebola epidemic would be over by now if they had been properly included in the outbreak response.
From broken bones to impotence to madness, these traditional healers say they have a potion, spell or touch for many ailments Western doctors can't treat. But there's only one cure for Ebola they say: knowledge.
In the forest region of southeastern Guinea, where the virus was detected last March, disseminating information using modern technology has proved challenging, resulting in the disease outstaying its welcome.
Karamoko Ibrahima Fofana, president of the association of traditional healers in the town of Macenta, said guérisseurs, as they are known, have unique access to remote villages.
"Guérisseurs are often the first port of call for the sick," said Fofana, 69, who is also an imam at the central mosque in Macenta, a hot, dusty town carved out of the forest.
"We could have spread information on how to protect against Ebola or told people with symptoms to seek help in the treatment centres."
Instead, the traditional healers were sometimes accused of spreading the deadly virus. After all, it was the claim of a guérisseur in Sierra Leone that she could cure Ebola that drew the first Guinean victims across the border, Fofana recalled.
Ebola has infected more than 23,500 people in West Africa and killed over 9,500, nearly all in the three worst-affected countries of Guinea, Liberia and Sierra Leone. It is transmitted through blood, vomit, diarrhoea and other bodily fluids.
.. View gallery
Ebola outbreak in West Africa
Ebola health care workers carry the body of a middle aged man that they suspected of dying from the …
Health officials are exploring ways to prevent similar disease outbreaks around the world, with epidemics expected to be a focus at a global conference on disaster risk reduction in Japan later this month.
Fofana admits the guérisseurs in his association didn't know what Ebola was at first, but after training from United Nations staff they're keen to spread information - and not the virus.
"If a guérisseur has been trained on Ebola and is then caught treating a suspected case, they are fined 50,000 GNF ($7), stripped of their membership and reported to the police," he told the Thomson Reuters Foundation.
WORD OF MOUTH
Jean Marie Dangou, head of the World Health Organisation (WHO) in Guinea, said the "Stop Ebola" campaign based on modern communication technology, had all but failed.
"For about one year the main communication strategy was built around media, mainly radio and TV, but it wasn't successful. The country is still dealing with tough and repetitive resistance," Dangou said.
West Africa has recorded some weekly declines in new confirmed cases of Ebola since the start of 2015, but resistance in some communities has undermined efforts to end the epidemic.
The main message from this outbreak is that communication must be adapted to fit the local culture, Dangou said.
.. View gallery
A health worker checks the temperature of a boy at …
A health worker checks the temperature of a boy at the entrance to a Red Cross facility in the town …
Word of mouth may be a better way of getting information out than modern methods in parts of the world where broadcast signals are weak and power for electrical appliances is scarce.
"Lessons learned from Ebola in Guinea can be applied to cholera, malaria or any other infectious disease in other parts of the world that rely on an oral tradition," Dangou added.
At the start of the outbreak, traditional healers were viewed as part of the problem, rather than being recruited to help halt the disease.
"Our communication was top down and the way we delivered the messages was wrong. We told people to stop doing things without explaining why," Dangou told the Thomson Reuters Foundation.
In a shift in policy, community leaders, including healers, are given information and asked to act on it as they see fit. As a result, many have appropriated the "Stop Ebola" messages.
Traditional healers are also supplementing disease surveillance and helping response teams that search for cases.
"Most traditional healers are now aware of the risk of treating Ebola patients. More and more patients are coming to health facilities after a referral from their healer," said Dangou.
Given their important role in efforts to stamp out Ebola, the services of traditional healers should come at a price, said Joseph Souro Mamadouno, 58, a Catholic guérisseur from Macenta.
"Ebola is here today, but it could be cholera tomorrow. We can spread health messages, but the government should cover costs of transport, food and the time we take off work," said Mamadouno, who also works at the local agriculture school.
According to the healers' association, some 2,000 herbal practitioners in Macenta, a district with a population of around 300,000 close to the Liberian border, are out of pocket as a result of the Ebola response.
Ebola shares symptoms with less serious diseases traditional healers say they can treat: fatigue, fever, headache, vomiting and diarrhoea. But now these cases are referred to hospitals.
Koly Beavogui, 80, an animist traditional healer from Macenta said she and other female guérisseurs have been reduced to begging for food from neighbours and foraging in the forest.
The scrawny woman, with a wrinkled face and toothless smile, used to treat five to six people a day, but now hardly sees anyone.
"When the sick come to see me, I only ask them to give me whatever they can afford, because we don't buy illness, so we shouldn't have to pay for treatments," said Beavogui, sitting outside her freshly-swept, mudbrick house.
But others are fearful of turning Ebola into an industry.
"I'm not in favour of incentives, because it looks like we are in an Ebola business. These people should become agents of change, in their own community, without any kind of payment," the WHO's Dangou said.
U.S., Liberia kick off trial of Ebola drug ZMapp
1 hour ago
Fauci, Director of the National Institute of Allergy and Infectious Diseases, testifies about the U.S. measles outbreak before a House Energy and Commerce Oversight and Investigations Subcommittee on Capitol Hill in Washington
Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, testifies about …
. CHICAGO (Reuters) - U.S. and Liberian researchers have started a clinical trial to test the safety and effectiveness of Mapp Biopharmaceutical Inc's Ebola drug ZMapp, an experimental treatment that has already been tried in a handful of Ebola patients, including two U.S. missionaries.
The trial, a joint effort by the Liberian government and the National Institute of Allergy and Infectious Diseases (NIAID), will be conducted in Liberia and the United States among adults and children infected with Ebola, NIAID said on Friday.
Although ZMapp has been used on a humanitarian basis in nine infected patients, there was no way to tell whether the treatment offered a statistically significant benefit, Dr. Anthony Fauci, director of the NIAID, said in a statement.
Fauci said the randomized trial should provide the scientific evidence needed to show whether ZMapp is safe and effective, and whether it can be used in the current outbreak in West Africa and in future outbreaks.
The trial will enroll adults and children admitted to Ebola treatment units in Liberia, health care workers infected with Ebola virus in West Africa who have returned to the United States for treatment, and adults and children who may have acquired Ebola in the United States through secondary transmission.
Everyone in the study will receive the highest standard of care for treating Ebola. In addition, a portion of participants will also receive three doses of ZMapp. People in the study will be followed for up to a month after discharge.
The U.S. Biomedical Advanced Research and Development Authority is funding the production of ZMapp, a cocktail of antibodies made in tobacco plants.
If ZMapp proves effective, it will become part of the standard of care and a new treatment will be randomly assigned to portion of the patients.
Other drugs to be tested include a treatment from Canadian drugmaker Tekmira, the antiviral Favipiravir from Japan's Toyama Chemical Co, blood plasma collected from Ebola survivors, the drug BCX4430 from North Carolina-based BioCryst, and a treatment called AVI-7537 from Sarepta of Massachusetts. Each drug will be tested in up to 100 people per arm.
The trial is expected to conclude in December 2016, although scientists say they may need to be flexible as the Ebola epidemic wanes.
Guinea, Liberia and Sierra Leone reported 99 new confirmed Ebola cases in the week to Feb. 22, down from 128 the previous week, the WHO said on Wednesday.
They are putting all of this out there now. Getting ready for the order inflows. Why else would they be spending so much money in the next 6 months. If people would just stop and listen or read what taser is doing would be wise to jump in now.
Sentiment: Strong Buy
theflyonthewallcom: TASER recovers some of losses after analyst says post-earnings slide overdone
The shares of TASER (TASR) are recovering a bit of yesterday's losses after research firm Craig-Hallum wrote that the decline in the stock following the company's fourth quarter results was "a massive overreaction." The drop in the shares has created "a highly attractive entry point for long-term investors," the firm added. BACKGROUND: TASER, which sells electrical weapons and body cameras for police officers, reported higher than expected fourth quarter revenue but lower than expected profit yesterday. The company noted that it had taken reserves for obsolete inventory, causing its gross margin to decline versus the same period a year earlier. Additionally, TASER's sales, general and administrative expenses climbed $2.8M versus the same period a year earlier. WHAT'S NEW: TASER's bookings for its police body cameras jumped 60% in Q4, versus the previous quarter, Craig-Hallum analyst Steven Dyer reported. Of the video deals booked last quarter, 87% were five year deals, he noted, adding that the company booked "very few" five year deals in the fourth quarter of 2013. Furthermore, TASER's average revenue per user surged over 20% in Q4 compared with the previous quarter, Dyer stated. Estimating that TASER's video business is growing 100% annually, the analyst believes that the business will generate $100M in revenue in 2017 and is worth $12 per share. Its weapons business is worth $16 per share, according to the analyst, who estimated that the business generates roughly 80c per share in annual profits and has a great deal of room to grow overseas. TASER has $2 per share in cash, making the stock worth $30, according to Dyer, who raised his price target on the shares to $30 from $22. He reiterated a Buy rating on the stock. PRICE ACTION: In early afternoon trading, TASER rose 56c, or 2.5%, to $23.25. Yesterday the stock fell more than 16%. :theflyonthewallcom
Sentiment: Strong Buy
what I say. this is why we are coming back today.
Sentiment: Strong Buy